Global Cancer Diagnostics market and Drivers, Restraints, and Opportunities 2018-2024
Global Cancer Diagnostics Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Cancer diagnostic testing involves tests and procedures that confirms the presence of disease and identify the correct tumor type, location, extent and stage which will help physician to give the appropriate treatment. Biopsy, imaging tests, nuclear medicine scans, tumor biomarker tests are some of the diagnostic tests used for cancer diagnostics. According to the estimation of National cancer institute, in US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. Canada has estimated 202,400 new cases of cancer and nearly 78,000 deaths according to Canadian cancer society in 2016. While in Europe, 1.3 million people were diagnosed in 2015. According to National cancer institute, nearly 60% new cases of cancer are from Asia, Africa, Central and South American countries and nearly 70% of cancer deaths are also from this region. China has witnessed 4.3 million new cases of cancer and 2.8 million deaths in 2015. According to Indian council for medical research, India accounts for 1.4 million new cases of cancer and 736,000 cancer related death in 2016.
The cancer diagnostics market is booming due to increasing incidence of cancer globally, growing elderly population across the globe, increased use of personalized medicine in clinical practice, and development of new novel technologies such as nanotechnology. However, lack of skilled labors and high cost of diagnosis are some of the factors hampering the market growth to an extent.
Market Analysis: The “Global Cancer Diagnostics Market” is estimated to witness a CAGR of 11.6% during the forecast period 2018–2024. The market is analyzed based on four segments – method of diagnosis, application, end-user and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The North America is set to be the leading region for the cancer diagnostics market growth followed by Europe, Asia Pacific and Rest of the World.
Method of diagnosis Analysis: The global Cancer Diagnostics market by method of diagnosis is segmented into tumor biomarker tests, tissue diagnostics (biopsy), liquid biopsy, imaging, and others. Imaging occupied the largest share in 2017, and liquid biopsy is expected to grow at a high CAGR in the coming years due to high preference of molecular based non-invasive tests, and increasing adoption of personalized medicine. Imaging is further segmented into magnetic resonance imaging, computed tomography, ultrasound, mammography, and nuclear imaging.
Application Analysis: The global cancer diagnostics market by application is segmented into lung cancer, breast cancer, Colorectal cancer, prostate cancer and others. Lung cancer occupied the largest share in 2017, and breast cancer application is expected to be fastest growing segment during the forecasted period.
End-Users Analysis: The global cancer diagnostics market by end-users is segmented into Hospitals, diagnostic laboratories, academic & research institutes and others. Hospitals occupies a major share of cancer diagnostics market in 2017 and is expected to be same for next five years.
Key Players: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Inc., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., GE Healthcare, Qiagen N.V., Agilent Technologies, Inc., Hologic, Inc., Koninklijke Philips N. V. and other predominate & niche players.
Competitive Analysis: Currently, the imaging dominates the global cancer diagnostics market. The existing leading players and other predominant market players are concentrating on this market to offer advanced products. The key market players are acquiring other companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, key players are also launching new products to have edge in this market. For instance, in July 2017, the MEDITE Cancer Diagnostics, Inc., announced the launch of SureCyte C1 fluorogenic instant staining product universally. In April 2017, Roche announced the launch of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody, for the diagnosis of prostate cancer.
Benefits: The report provides complete details about the usage and adoption rate of cancer diagnostics products in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the product adoption in the upcoming years along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
Overview: Cancer diagnostic testing involves tests and procedures that confirms the presence of disease and identify the correct tumor type, location, extent and stage which will help physician to give the appropriate treatment. Biopsy, imaging tests, nuclear medicine scans, tumor biomarker tests are some of the diagnostic tests used for cancer diagnostics. According to the estimation of National cancer institute, in US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. Canada has estimated 202,400 new cases of cancer and nearly 78,000 deaths according to Canadian cancer society in 2016. While in Europe, 1.3 million people were diagnosed in 2015. According to National cancer institute, nearly 60% new cases of cancer are from Asia, Africa, Central and South American countries and nearly 70% of cancer deaths are also from this region. China has witnessed 4.3 million new cases of cancer and 2.8 million deaths in 2015. According to Indian council for medical research, India accounts for 1.4 million new cases of cancer and 736,000 cancer related death in 2016.
The cancer diagnostics market is booming due to increasing incidence of cancer globally, growing elderly population across the globe, increased use of personalized medicine in clinical practice, and development of new novel technologies such as nanotechnology. However, lack of skilled labors and high cost of diagnosis are some of the factors hampering the market growth to an extent.
Market Analysis: The “Global Cancer Diagnostics Market” is estimated to witness a CAGR of 11.6% during the forecast period 2018–2024. The market is analyzed based on four segments – method of diagnosis, application, end-user and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The North America is set to be the leading region for the cancer diagnostics market growth followed by Europe, Asia Pacific and Rest of the World.
Method of diagnosis Analysis: The global Cancer Diagnostics market by method of diagnosis is segmented into tumor biomarker tests, tissue diagnostics (biopsy), liquid biopsy, imaging, and others. Imaging occupied the largest share in 2017, and liquid biopsy is expected to grow at a high CAGR in the coming years due to high preference of molecular based non-invasive tests, and increasing adoption of personalized medicine. Imaging is further segmented into magnetic resonance imaging, computed tomography, ultrasound, mammography, and nuclear imaging.
Application Analysis: The global cancer diagnostics market by application is segmented into lung cancer, breast cancer, Colorectal cancer, prostate cancer and others. Lung cancer occupied the largest share in 2017, and breast cancer application is expected to be fastest growing segment during the forecasted period.
End-Users Analysis: The global cancer diagnostics market by end-users is segmented into Hospitals, diagnostic laboratories, academic & research institutes and others. Hospitals occupies a major share of cancer diagnostics market in 2017 and is expected to be same for next five years.
Key Players: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Inc., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., GE Healthcare, Qiagen N.V., Agilent Technologies, Inc., Hologic, Inc., Koninklijke Philips N. V. and other predominate & niche players.
Competitive Analysis: Currently, the imaging dominates the global cancer diagnostics market. The existing leading players and other predominant market players are concentrating on this market to offer advanced products. The key market players are acquiring other companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, key players are also launching new products to have edge in this market. For instance, in July 2017, the MEDITE Cancer Diagnostics, Inc., announced the launch of SureCyte C1 fluorogenic instant staining product universally. In April 2017, Roche announced the launch of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody, for the diagnosis of prostate cancer.
Benefits: The report provides complete details about the usage and adoption rate of cancer diagnostics products in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the product adoption in the upcoming years along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
1 INDUSTRY OUTLOOK
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Advantage of cancer diagnostics
3.3 Disadvantage of cancer diagnostics
3.4 Segmented Addressable Market (SAM)
3.5 Trends of the cancer diagnostics market
3.6 Related Markets
3.6.1 Companion diagnostics
3.6.2 Genetic testing
3.6.3 Point-of-Care Diagnostics
4 MARKET OUTLOOK
4.1 Overview
4.2 Funding scenario
4.3 Market segmentation
4.4 PEST Analysis
4.5 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Cancer Diagnostics Market Dynamics
5.1.1 Drivers
5.1.1.1 Rising incidence of cancer globally
5.1.1.2 Growing geriatric population
5.1.1.3 Growing demand of personalized medicine
5.1.2 Opportunities
5.1.2.1 Revolutionary nanotechnology in cancer diagnostics
5.1.2.2 Increasing medical tourism
5.1.3 Restraints
5.1.3.1 High cost of diagnosis
5.1.3.2 Lack of skilled professionals
6 METHOD OF DIAGNOSIS: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Tumor biomarker tests
6.3 Tissue diagnostics
6.4 Liquid biopsy
6.5 Imaging
6.5.1 Magnetic resonance imaging (MRI)
6.5.2 Computed tomography (CT)
6.5.3 Ultrasound
6.5.4 Mammography
6.5.5 Nuclear imaging
6.6 Others
7 APPLICATION: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Lung cancer
7.3 Breast cancer
7.4 Colorectal cancer
7.5 Prostate cancer
7.6 Others
8 END USERS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Hospitals
8.3 Diagnostic Laboratories
8.4 Academic & research institutes
8.5 Others
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 North America
9.2.1 Overview
9.2.2 US
9.2.3 Canada
9.3 Europe
9.3.1 Overview
9.3.2 UK
9.3.3 Germany
9.3.4 France
9.3.5 Spain
9.4 APAC
9.4.1 Overview
9.4.2 India
9.4.3 China
9.5 Rest of the World
10 COMPETITIVE LANDSCAPE
10.1 Overview
11 VENDOR PROFILES
11.1 F.Hoffmann-La Roche Ltd
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Presence
11.1.4
11.1.5 Business Focus
11.1.6 SWOT Analysis
11.1.7 Business Strategy
11.2 Abbott Laboratories
11.2.1 Overview
11.2.2 Business Unit
11.2.3 Geographic Presence
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategy
11.3 Siemens Healthineers (Siemens AG)
11.3.1 Overview
11.3.2 Business Units
11.3.3 Geographic Presence
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategy
11.4 Thermo Fisher Scientific Inc.
11.4.1 Overview
11.4.2 Geographic Presence
11.4.3 Business Focus
11.4.4 SWOT Analysis
11.4.5 Business Strategies
11.5 GE Healthcare
11.5.1 Overview
11.5.1.1 Business unit
11.5.1.2 Business focus
11.5.1.3 SWOT analysis
11.5.2 Business Strategy
12 COMPANIES TO WATCH FOR
12.1 Qiagen N.V.
12.1.1 Overview
12.2 BioMerieux S.A.
12.2.1 Overview
12.2.2 BioMerieux S.A.: Recent Developments
12.3 Agilent Technologies, Inc
12.3.1 Overview
12.3.2 Agilent Technologies: Recent Developments
12.4 Becton Dickinson and Company
12.4.1 Overview
12.4.2 Becton dickenson and company: Recent Developments
12.5 Hologic Inc.
12.5.1 Overview
12.5.2 Hologic Inc.: Recent Developments
12.6 Illumina, Inc.
12.6.1 Overview
12.6.2 Illumina Inc.: Recent Developments
12.7 Koninklijke Philips N.V.
12.7.1 Overview
12.7.2 Koninklijke Philips N.V.: Recent Developments
13 ANNEXURE
13.1 Abbreviations
Tables
Table 1 FUNDING SCENARIO
Table 2 GLOBAL CANCER DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 3 OTHER PROMINENT VENDORS OF CANCER DIAGNOSTICS MARKET
Table 4 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 5 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 6 ABBOTT LABORATORIES: PRODUCT OFFERINGS
Table 7 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 8 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 9 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 10 THERMO FISHER SCIENTIFIC INC.: PRODUCT OFFERINGS
Table 11 THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
Table 12 GE HEALTHCARE: PRODUCT OFFERINGS
Table 13 GE HEALTHCARE: RECENT DEVELOPMENTS
Table 14 QIAGEN N.V.: SNAPSHOT
Table 15 QIAGEN N.V.: RECENT DEVELOPMENTS
Table 16 BIOMERIEUX S.A.: SNAPSHOT
Table 17 AGILENT TECHNOLOGIES: SNAPSHOT
Table 18 BECTON DICKINSON AND COMPANY: SNAPSHOT
Table 19 HOLOGIC INC.: SNAPSHOT
Table 20 ILLUMINA INC: SNAPSHOT
Table 21 KONINKLIJKE PHILIPS N.V.: SNAPSHOT
?
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL CANCER DIAGNOSTICS MARKET
Chart 2 GLOBAL CANCER DIAGNOSTICS MARKET REVENUE, 2017–2024 ($MILLION)
Chart 3 SEGMENTATION OF GLOBAL CANCER DIAGNOSTICS MARKET
Chart 4 PEST ANALYSIS OF GLOBAL CANCER DIAGNOSTICS MARKET
Chart 5 PORTER 5 FORCES ON GLOBAL CANCER DIAGNOSTICS MARKET
Chart 6 DRO – IMPACT ANALYSIS OF GLOBAL CANCER DIAGNOSTICS MARKET
Chart 7 KEY STAKEHOLDERS
Chart 8 GLOBAL CANCER DIAGNOSTICS MARKET BY METHOD OF DIAGNOSIS SEGMENTATION, 2017 (%)
Chart 9 GLOBAL CANCER DIAGNOSTICS MARKET BY METHOD OF DIAGNOSIS SEGMENTATION, 2017 (%)
Chart 10 GLOBAL TUMOUR BIOMARKER TESTSING MARKET FORECAST, 2017–2024 ($MILLION)
Chart 11 GLOBAL TISSUE DIAGNOSTICS MARKET FORECAST, 2017–2024 ($MILLION)
Chart 12 GLOBAL LIQUID BIOPSY MARKET FORECAST, 2017–2024 ($MILLION)
Chart 13 GLOBAL IMAGING MARKET FORECAST, 2017–2024 ($MILLION)
Chart 14 GLOBAL IMAGING MARKET BY TYPE SEGMENTATION, 2017 (%)
Chart 15 GLOBAL OTHERS MARKET FORECAST, 2017–2024 ($MILLION)
Chart 16 GLOBAL CANCER DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%)
Chart 17 GLOBAL CANCER DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%)
Chart 18 GLOBAL CANCER DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 19 CANCER DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION)
Chart 20 CANCER DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
Chart 21 CANCER DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017–2024 ($MILLION)
Chart 22 CANCER DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 27 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT
Chart 28 ABBOTT LABORATORIES.: BUSINESS UNITS
Chart 29 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
Chart 30 ABBOTT LABORATORIES.: SWOT ANALYSIS
Chart 31 SIEMENS AG: OVERVIEW SNAPSHOT
Chart 32 SIEMENS AG: BUSINESS UNITS
Chart 33 SIEMENS AG: GEOGRAPHIC PRESENCE
Chart 34 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS
Chart 35 THERMO FISHER SCIENTIFIC INC.: OVERVIEW SNAPSHOT
Chart 36 THERMO FISHER SCIENTIFIC INC.: BUSINESS UNITS REVENUE
Chart 37 THERMO FISHER SCIENTIFIC INC.: GEOGRAPHICAL PRESENCE
Chart 38 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
Chart 39 GE HEALTHCARE: OVERVIEW SNAPSHOT
Chart 40 GE HELATHCARE: BUSINES UNITS
Chart 41 GE HEALTHACRE: GEOGRAPHY
Chart 42 GE HEALTHCARE: SWOT ANALYSIS
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Advantage of cancer diagnostics
3.3 Disadvantage of cancer diagnostics
3.4 Segmented Addressable Market (SAM)
3.5 Trends of the cancer diagnostics market
3.6 Related Markets
3.6.1 Companion diagnostics
3.6.2 Genetic testing
3.6.3 Point-of-Care Diagnostics
4 MARKET OUTLOOK
4.1 Overview
4.2 Funding scenario
4.3 Market segmentation
4.4 PEST Analysis
4.5 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Cancer Diagnostics Market Dynamics
5.1.1 Drivers
5.1.1.1 Rising incidence of cancer globally
5.1.1.2 Growing geriatric population
5.1.1.3 Growing demand of personalized medicine
5.1.2 Opportunities
5.1.2.1 Revolutionary nanotechnology in cancer diagnostics
5.1.2.2 Increasing medical tourism
5.1.3 Restraints
5.1.3.1 High cost of diagnosis
5.1.3.2 Lack of skilled professionals
6 METHOD OF DIAGNOSIS: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Tumor biomarker tests
6.3 Tissue diagnostics
6.4 Liquid biopsy
6.5 Imaging
6.5.1 Magnetic resonance imaging (MRI)
6.5.2 Computed tomography (CT)
6.5.3 Ultrasound
6.5.4 Mammography
6.5.5 Nuclear imaging
6.6 Others
7 APPLICATION: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Lung cancer
7.3 Breast cancer
7.4 Colorectal cancer
7.5 Prostate cancer
7.6 Others
8 END USERS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Hospitals
8.3 Diagnostic Laboratories
8.4 Academic & research institutes
8.5 Others
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 North America
9.2.1 Overview
9.2.2 US
9.2.3 Canada
9.3 Europe
9.3.1 Overview
9.3.2 UK
9.3.3 Germany
9.3.4 France
9.3.5 Spain
9.4 APAC
9.4.1 Overview
9.4.2 India
9.4.3 China
9.5 Rest of the World
10 COMPETITIVE LANDSCAPE
10.1 Overview
11 VENDOR PROFILES
11.1 F.Hoffmann-La Roche Ltd
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Presence
11.1.4
11.1.5 Business Focus
11.1.6 SWOT Analysis
11.1.7 Business Strategy
11.2 Abbott Laboratories
11.2.1 Overview
11.2.2 Business Unit
11.2.3 Geographic Presence
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategy
11.3 Siemens Healthineers (Siemens AG)
11.3.1 Overview
11.3.2 Business Units
11.3.3 Geographic Presence
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategy
11.4 Thermo Fisher Scientific Inc.
11.4.1 Overview
11.4.2 Geographic Presence
11.4.3 Business Focus
11.4.4 SWOT Analysis
11.4.5 Business Strategies
11.5 GE Healthcare
11.5.1 Overview
11.5.1.1 Business unit
11.5.1.2 Business focus
11.5.1.3 SWOT analysis
11.5.2 Business Strategy
12 COMPANIES TO WATCH FOR
12.1 Qiagen N.V.
12.1.1 Overview
12.2 BioMerieux S.A.
12.2.1 Overview
12.2.2 BioMerieux S.A.: Recent Developments
12.3 Agilent Technologies, Inc
12.3.1 Overview
12.3.2 Agilent Technologies: Recent Developments
12.4 Becton Dickinson and Company
12.4.1 Overview
12.4.2 Becton dickenson and company: Recent Developments
12.5 Hologic Inc.
12.5.1 Overview
12.5.2 Hologic Inc.: Recent Developments
12.6 Illumina, Inc.
12.6.1 Overview
12.6.2 Illumina Inc.: Recent Developments
12.7 Koninklijke Philips N.V.
12.7.1 Overview
12.7.2 Koninklijke Philips N.V.: Recent Developments
13 ANNEXURE
13.1 Abbreviations
Tables
Table 1 FUNDING SCENARIO
Table 2 GLOBAL CANCER DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 3 OTHER PROMINENT VENDORS OF CANCER DIAGNOSTICS MARKET
Table 4 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 5 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 6 ABBOTT LABORATORIES: PRODUCT OFFERINGS
Table 7 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 8 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 9 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 10 THERMO FISHER SCIENTIFIC INC.: PRODUCT OFFERINGS
Table 11 THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
Table 12 GE HEALTHCARE: PRODUCT OFFERINGS
Table 13 GE HEALTHCARE: RECENT DEVELOPMENTS
Table 14 QIAGEN N.V.: SNAPSHOT
Table 15 QIAGEN N.V.: RECENT DEVELOPMENTS
Table 16 BIOMERIEUX S.A.: SNAPSHOT
Table 17 AGILENT TECHNOLOGIES: SNAPSHOT
Table 18 BECTON DICKINSON AND COMPANY: SNAPSHOT
Table 19 HOLOGIC INC.: SNAPSHOT
Table 20 ILLUMINA INC: SNAPSHOT
Table 21 KONINKLIJKE PHILIPS N.V.: SNAPSHOT
?
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL CANCER DIAGNOSTICS MARKET
Chart 2 GLOBAL CANCER DIAGNOSTICS MARKET REVENUE, 2017–2024 ($MILLION)
Chart 3 SEGMENTATION OF GLOBAL CANCER DIAGNOSTICS MARKET
Chart 4 PEST ANALYSIS OF GLOBAL CANCER DIAGNOSTICS MARKET
Chart 5 PORTER 5 FORCES ON GLOBAL CANCER DIAGNOSTICS MARKET
Chart 6 DRO – IMPACT ANALYSIS OF GLOBAL CANCER DIAGNOSTICS MARKET
Chart 7 KEY STAKEHOLDERS
Chart 8 GLOBAL CANCER DIAGNOSTICS MARKET BY METHOD OF DIAGNOSIS SEGMENTATION, 2017 (%)
Chart 9 GLOBAL CANCER DIAGNOSTICS MARKET BY METHOD OF DIAGNOSIS SEGMENTATION, 2017 (%)
Chart 10 GLOBAL TUMOUR BIOMARKER TESTSING MARKET FORECAST, 2017–2024 ($MILLION)
Chart 11 GLOBAL TISSUE DIAGNOSTICS MARKET FORECAST, 2017–2024 ($MILLION)
Chart 12 GLOBAL LIQUID BIOPSY MARKET FORECAST, 2017–2024 ($MILLION)
Chart 13 GLOBAL IMAGING MARKET FORECAST, 2017–2024 ($MILLION)
Chart 14 GLOBAL IMAGING MARKET BY TYPE SEGMENTATION, 2017 (%)
Chart 15 GLOBAL OTHERS MARKET FORECAST, 2017–2024 ($MILLION)
Chart 16 GLOBAL CANCER DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%)
Chart 17 GLOBAL CANCER DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%)
Chart 18 GLOBAL CANCER DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 19 CANCER DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION)
Chart 20 CANCER DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
Chart 21 CANCER DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017–2024 ($MILLION)
Chart 22 CANCER DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 27 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT
Chart 28 ABBOTT LABORATORIES.: BUSINESS UNITS
Chart 29 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
Chart 30 ABBOTT LABORATORIES.: SWOT ANALYSIS
Chart 31 SIEMENS AG: OVERVIEW SNAPSHOT
Chart 32 SIEMENS AG: BUSINESS UNITS
Chart 33 SIEMENS AG: GEOGRAPHIC PRESENCE
Chart 34 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS
Chart 35 THERMO FISHER SCIENTIFIC INC.: OVERVIEW SNAPSHOT
Chart 36 THERMO FISHER SCIENTIFIC INC.: BUSINESS UNITS REVENUE
Chart 37 THERMO FISHER SCIENTIFIC INC.: GEOGRAPHICAL PRESENCE
Chart 38 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
Chart 39 GE HEALTHCARE: OVERVIEW SNAPSHOT
Chart 40 GE HELATHCARE: BUSINES UNITS
Chart 41 GE HEALTHACRE: GEOGRAPHY
Chart 42 GE HEALTHCARE: SWOT ANALYSIS
